Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis

Cancer

Volumn 122, Issue 7, 2016, Pages 1085-1096

  Sanyal, Chiranjeev ^a   Aprikian, Armen G ^a   Cury, Fabio L ^a,b   Chevalier, Simone ^a   Dragomir, Alice ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

costs; decision analysis; health economics; outcomes research; prostate cancer; quality adjusted life years (QALYs)

Indexed keywords

ABIRATERONE; BICALUTAMIDE; DOCETAXEL;

ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANADA; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; DRUG COST; ERECTILE DYSFUNCTION; GYNECOMASTIA; HEALTH CARE COST; HEART DISEASE; HOSPITALIZATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; COST OF ILLNESS; ECONOMICS; MARKOV CHAIN; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA;

CANADA; COHORT STUDIES; COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; MONTE CARLO METHOD; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84957553262     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29892     Document Type: Article

References (51)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
3. Canadian Cancer Society. Canadian cancer statistics. http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on. Accessed July 17, 2015.
4. National Comprehensive Cancer Network. NCCN guidelines. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site. Accessed July 17, 2015.
5. Heidenreich A, Bastian PJ, Bellmunt J, et al,; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014; 65: 124-137.
6. Heidenreich A, Bastian PJ, Bellmunt J, et al,; European Association of Urology. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014; 65: 467-479.
7. Saad F, Hotte S, Catton C, et al., CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. Can Urol Assoc J. 2013; 7: 231-237.
8. American Cancer Society. Cancer Facts & Figures 2014. http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed July 17, 2015.
9. Grover SA, Coupal L, Zowall H, et al., The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ. 2000; 162: 987-992.
10. Stokes ME, Ishak J, Proskorovsky I, Black LK, Huang Y,. Lifetime economic burden of prostate cancer. BMC Health Serv Res. 2011; 11: 349.
11. Nguyen PL, Gu X, Lipsitz SR, et al., Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011; 29: 1517-1524.
12. Dragomir A, Cury FL, Aprikian AG,. Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. CMAJ Open. 2014; 2: E60-E68.
13. Dragomir A, Dinea D, Vanhuyse M, Cury FL, Aprikian AG,. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Serv Res. 2014; 14: 252.
14. Hayes JH, Ollendorf DA, Pearson SD, et al., Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med. 2013; 158: 853-860.
15. Cooperberg MR, Ramakrishna NR, Duff SB, et al., Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013; 111: 437-450.
16. Yong JH, Beca J, McGowan T, Bremner KE, Warde P, Hoch JS,. Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer. Clin Oncol (R Coll Radiol). 2012; 24: 521-531.
17. Iannazzo S, Pradelli L, Carsi M, Perachino M,. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. Value Health. 2011; 14: 80-89.
18. Holko P, Kawalec P,. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2014; 14: 63-73.
19. Gong CL, Hay JW,. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw. 2014; 12: 1417-1425.
20. Koerber F, Waidelich R, Stollenwerk B, Rogowski W,. The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer. BMC Health Serv Res. 2014; 14: 163.
21. Sanyal C, Aprikian A, Cury F, Chevalier S, Dragomir A,. Clinical management and burden of prostate cancer: a Markov Monte Carlo model. PLoS One. 2014; 9: e113432.
22. Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, Peschel RE,. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol. 2009; 93: 185-191.
23. Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC,. Radical prostatectomy for clinical stage T3a disease. Cancer. 2007; 109: 1273-1278.
24. Pataky R, Gulati R, Etzioni R, et al., Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer. 2014; 135: 939-947.
25. Spratt DE, Zumsteg ZS, Ghadjar P, et al., Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int. 2014; 114: 360-367.
26. Kotecha R, Yamada Y, Pei X, et al., Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy. 2013; 12: 44-49.
27. Krahn MD, Bremner KE, Luo J, Alibhai SM,. Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events. Curr Oncol. 2014; 21: e457-e465.
28. Fizazi K, Carducci M, Smith M, et al., Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377: 813-822.
29. Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M,. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol. 2005; 174: 547-552; discussion 552.
30. Tannock IF, de Wit R, Berry WR, et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512.
31. de Bono JS, Logothetis CJ, Molina A, et al,; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005.
32. Krahn M, Ritvo P, Irvine J, et al., Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003; 41: 153-164.
33. Canadian Agency for Drugs and Technologies in Health. Therapeutic Review: Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared With Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation. Ottawa, Ontario, Canada: Canadian Collaborative for Drug Safety, Effectiveness and Network Meta-Analysis; 2012.
34. Siebert U, Alagoz O, Bayoumi AM, et al,; ISPOR-SMDM Modeling Good Research Practices Task Force. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value Health. 2012; 15: 812-820.
35. Krahn MD, Bremner KE, Zagorski B, et al., Health care costs for state transition models in prostate cancer. Med Decis Making. 2014; 34: 366-378.
36. Statistics Canada. Consumer price index. http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=3260021&paSer=&pattern=&stByVal=1&p1=1&p2=37&tabMode=dataTable&csid=. Accessed July 17, 2015.
37. Kulkarni GS, Alibhai SM, Finelli A, et al., Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer. 2009; 115: 5450-5459.
38. Regie de l'Assurance Maladie du Quebec. Manuel of Medical Specialists. Vol 86 Update. Quebec City, Quebec, Canada: Regie de l'Assurance Maladie du Quebec; 2014.
39. Perrault L, Fradet V, Lauzon V, LeLorier J, Mitchell D, Habib M,. Burden of illness of bone metastases in prostate cancer patients in Quebec, Canada: a population-based analysis. Can Urol Assoc J. 2015; 9: 307-314.
40. Lathia N, Mittmann N, DeAngelis C, et al., Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer. 2010; 116: 742-748.
41. Poulin F, Khairy P, Roy D, et al,; Atrial Fibrillation and Congestive Heart Failure Trial Investigators. Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies. Can J Cardiol. 2013; 29: 1256-1262.
42. Drummond MF, Torrance GW, O'Brien BJ, Stoddart GL,. Methods for the Economic Evaluation of Health Care Programme. 3rd ed. Oxford, UK: Oxford University Press; 2005.
43. Canadian Agency for Drugs and Technologies in Health. Guidelines for economic evaluation of health technologies: Canada, 2006. http://www.cadth.ca/en/products/methods-and-guidelines/overview. Accessed July 17, 2015.
44. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP,. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012; 118: 3512-3518.
45. Alemayehu B, Buysman E, Parry D, Becker L, Nathan F,. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ. 2010; 13: 351-361.
46. Bodenheimer T,. High and rising health care costs. Part 2: technologic innovation. Ann Intern Med. 2005; 142: 932-937.
47. Bodenheimer T,. High and rising health care costs. Part 1: seeking an explanation. Ann Intern Med. 2005; 142: 847-854.
48. Bodenheimer T, Fernandez A,. High and rising health care costs. Part 4: can costs be controlled while preserving quality? Ann Intern Med. 2005; 143: 26-31.
49. Hunink M, Glasziou P, Siegel JE, et al., Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge, UK: Cambridge University Press; 2001.
50. Close A, Robertson C, Rushton S, et al., Comparative cost-effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of men with localised prostate cancer: a health technology assessment from the perspective of the UK National Health Service. Eur Urol. 2013; 64: 361-369.
51. Hayes JH, Ollendorf DA, Pearson SD, et al., Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010; 304: 2373-2380.